Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
159 hedge funds and large institutions have $612M invested in Progenics Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 16 closing their positions.
250% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 16
69% more call options, than puts
Call options by funds: $6.1M | Put options by funds: $3.62M
26% more funds holding
Funds holding: 126 → 159 (+33)
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
18% more capital invested
Capital invested by funds: $518M → $612M (+$93.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$95M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$12.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$10.3M |
| 5 |
Goldman Sachs
New York
|
+$5.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$69.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.91M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.13M |
| 4 |
RA
Royce & Associates
New York
|
-$2.08M |
| 5 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$1.9M |
PGNX Hedge Fund Activity: Q1 2017 in Review
159 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2017, worth a combined $612M — up 18% from $518M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new PGNX positions and 16 closed out — a net gain of 40 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was BlackRock, adding an estimated $95M. The largest seller was Broadfin Capital, cutting an estimated $69.4M.
- 159 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2017, up from 126 in Q4 2016.
- Funds reported $612M of Progenics Pharmaceuticals Inc stock for Q1 2017, up 18% quarter-over-quarter.
- 56 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2017 and 16 closed out, a net change of +40 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $95M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2017 was Broadfin Capital, an estimated $69.4M sold.
Based on aggregated 13F filings for Q1 2017.